The use of modified chimeric antigen receptor (CAR) T cells (CAR-T) in immunotherapy has significantly improved the survival rates of pediatric patients with relapsed leukemia. However, these therapies are not as effectiveRead More…
In a recent study, researchers from Stanford University in the United States collected data from previous studies on CAR-T cell therapy to investigate the reactivation of human herpesvirus 6 (HHV-6) in patientsRead More…
In recent years, scientists have harnessed the power of gene editing technology to reprogram immune cells into therapies capable of targeting cancer. However, these immunotherapies are not universally effective across all patientsRead More…
In a recent study, researchers from the University of Illinois Urbana-Champaign in the United States have discovered that CAR-T cell immunotherapy could potentially be a highly effective treatment for solid tumors ifRead More…
A small-scale clinical trial suggests that an improved form of CAR-T cell therapy, known as Descartes-08, holds promise for treating myasthenia gravis, an autoimmune neuromuscular disease. The modified CAR-T therapy used inRead More…
At the end of June this year, the CAR-NK cell, a new immune cell, was reported as the third CAR cell to fight against cancer after CAR-T cells and CAR-macrophage cells. TheRead More…